Gilead Sciences Files $500 Million Shelf Registration Statement

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 22, 2003--Gilead Sciences, Inc. (Nasdaq:GILD - ) today announced that it has filed a universal shelf registration statement with the U.S. Securities and Exchange Commission ("SEC") for the registration and potential issuance of up to $500 million of Gilead securities which may include common stock, preferred stock, convertible debt or other securities. Upon being declared effective by the SEC, the shelf registration statement will allow the Company to sell the various securities in one or more offerings in the future. The Company has no immediate plans to sell any securities under this shelf registration.

A registration statement relating to the securities listed in the shelf registration statement has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

     Gilead Sciences, Inc.
     Susan Hubbard, 650-522-5715 (Investors)
     Erin Edgley, 650-522-5635 (Media)